Biomaterial Database

[Immunodiagnosis and immunotherapy of allergic forms]. 1980

G C Tassi, and E Ghezzi, and M R Sorzini, and M Zappa

The Authors outline the immunological and immunopathogenic bases of atopy, pointing out the possible mechanisms involved in the impaired control capacity on IgE synthesis (hyperreactivity of NK cells, histamine-H2 receptors interaction, adenylcyclase stimulation, etc.). The in vivo and in vitro techniques employed in the allergological diagnosis are examined, with particular reference to the more recent tests (RAST, RAST Spot Test, Histamine radioenzymatic assay, in vitro IgE spontaneous synthesis, etc.). The latest findings in the allergological immunotherapy are then surveyed, including both the antigen non specific immunotherapy and the relevant possibility of inducing a non specific suppressor mechanism of the IgE response, and the antigen specific immunotherapy, which, besides the classical (aqueous, retard) vaccines, exploits the monovalent allergenic extracts, the allergoids (formaldehyde and glutaraldehyde) and the modified allergens (urea, PEG/PVA, D-GL, polysaccharides, photooxydation).

UI	MeSH Term	Description	Entries
D006967	Hypersensitivity	Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D006969	Hypersensitivity, Immediate	Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability.	Atopic Hypersensitivity,Hypersensitivity, Atopic,Hypersensitivity, Type I,IgE-Mediated Hypersensitivity,Type I Hypersensitivity,Atopic Hypersensitivities,Hypersensitivities, Atopic,Hypersensitivities, IgE-Mediated,Hypersensitivities, Immediate,Hypersensitivities, Type I,Hypersensitivity, IgE-Mediated,IgE Mediated Hypersensitivity,IgE-Mediated Hypersensitivities,Immediate Hypersensitivities,Immediate Hypersensitivity,Type I Hypersensitivities
D007073	Immunoglobulin E	An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).	IgE
D007112	Immunity, Maternally-Acquired	Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk.	Fetal Immunity, Maternally-Acquired,Maternally-Acquired Immunity,Neonatal Immunity, Maternally-Acquired,Immunity, Maternally Acquired,Fetal Immunities, Maternally-Acquired,Fetal Immunity, Maternally Acquired,Immunity, Maternally-Acquired Fetal,Immunity, Maternally-Acquired Neonatal,Maternally Acquired Immunities,Maternally Acquired Immunity,Maternally-Acquired Fetal Immunities,Maternally-Acquired Fetal Immunity,Maternally-Acquired Immunities,Maternally-Acquired Neonatal Immunities,Maternally-Acquired Neonatal Immunity,Neonatal Immunities, Maternally-Acquired,Neonatal Immunity, Maternally Acquired
D007165	Immunosuppression Therapy	Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.	Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007167	Immunotherapy	Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.	Immunotherapies
D007694	Killer Cells, Natural	Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.	NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D011852	Radioallergosorbent Test	An in vitro allergen radioimmunoassay in which allergens are coupled to an immunosorbent. The coupled allergens bind the IgE in the sera of patients which in turn binds radioisotope-labeled anti-IMMUNOGLOBULIN E antibodies.	Radioimmunosorbent Assay of Allergens,Allergens Radioimmunosorbent Assay,Allergens Radioimmunosorbent Assays,Radioallergosorbent Tests,Test, Radioallergosorbent,Tests, Radioallergosorbent
D011970	Receptors, Histamine H2	A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H2 receptors act via G-proteins to stimulate ADENYLYL CYCLASES. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (From Biochem Soc Trans 1992 Feb;20(1):122-5)	Histamine H2 Receptors,H2 Receptors,Receptors, H2,H2 Receptors, Histamine
D004789	Enzyme Activation	Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.	Activation, Enzyme,Activations, Enzyme,Enzyme Activations